Abstract
The Fmr1 knock-out mouse model of fragile X syndrome (Fmr1−/y) has an epileptogenic phenotype that is triggered by group I metabotropic glutamate receptor (mGluR) activation. We found that a membrane-permeable peptide that disrupts mGluR5 interactions with long-form Homers enhanced mGluR-induced epileptiform burst firing in wild-type (WT) animals, replicating the early stages of hyperexcitability in Fmr1−/y. The peptide enhanced mGluR-evoked endocannabinoid (eCB)-mediated suppression of inhibitory synapses, decreased it at excitatory synapses in WTs, but had no effect on eCB actions in Fmr1−/y. At a low concentration, the mGluR agonist did not generate eCBs at excitatory synapses but nevertheless induced burst firing in both Fmr1−/y and peptide-treated WT slices. This burst firing was suppressed by a cannabinoid receptor antagonist. We suggest that integrity of Homer scaffolds is essential for normal mGluR–eCB functioning and that aberrant eCB signaling resulting from disturbances of this molecular structure contributes to the epileptic phenotype of Fmr1−/y.
Introduction
Fragile X syndrome (FXS) is an autism spectrum disorder accompanied frequently by epileptic seizures. FXS is caused by transcriptional silencing of the gene Fmr1, which codes for fragile X mental retardation protein (FMRP; Darnell and Klann, 2013), a translation inhibitor that can be activated by group I metabotropic glutamate receptors (mGluRs; i.e., mGluR1 and mGluR5). Mice lacking Fmr1 (Fmr1−/y) have some behavioral abnormalities that mimic those in humans with FXS. According to the mGluR theory of FXS (Bear et al., 2004), the absence of FMRP allows mGluRs to generate excessive protein synthesis, which contributes to FXS pathology (Dölen et al., 2007). Persistent activation of group I mGluRs produces prolonged epileptiform discharges in Fmr1−/y mice (Chuang et al., 2005; Zhao et al., 2011; Osterweil et al., 2013). However, the hyperexcitability phenotype in FXS may not be explained by this mechanism alone; decreases in inhibitory transmission also occur in Fmr1−/y mice (Olmos-Serrano et al., 2010; Paluszkiewicz et al., 2011).
Activation of group I mGluRs efficiently mobilizes endocannabinoids (eCBs), eCBmGluR (Varma et al., 2001), that suppress transmitter release by stimulating CB1Rs, which are more concentrated on the presynaptic terminals of inhibitory than excitatory cells (Kano et al., 2009). eCBmGluR can cause short-term (Morishita et al., 1998) or long-term (for review, see Heifets and Castillo, 2009) synaptic depression of GABA or glutamate release. In Fmr1−/y mice, eCBmGluR at GABA synapses is enhanced in the hippocampus (Zhang and Alger, 2010) and striatum (Maccarrone et al., 2010) because of increased coupling between mGluRs and eCB mobilization.
Homer proteins anchor mGluRs to the postsynaptic density in spines (Klugmann and Szumlinski, 2008). Long-form Homer proteins mediate protein–protein interactions through tetramer formation, which is disrupted by the dominant-negative Homer 1a. Binding or unbinding Homers facilitate a variety of mGluR-dependent biochemical reactions, and, therefore, the Homer system acts as a molecular switch to reprioritize mGluR signaling (Kammermeier, 2008).
In expression systems (Jung et al., 2007) and dissociated cell culture (Roloff et al., 2010), Homer proteins regulate eCBmGluR. Interactions between mGluR5 and Homers are decreased in Fmr1−/y mice (Giuffrida et al., 2005; Ronesi and Huber, 2008). Manipulations of eCB signaling rescue various aspects of the Fmr1−/y phenotype (Jung et al., 2012; Busquets-Garcia et al., 2013). Homer 1a deletion partially reverses the Fmr1−/y phenotype (Ronesi et al., 2012), but the hypothesis that Homer proteins regulate eCBmGluR has not been tested.
We investigated (S)-3,5-dihydroxyphenylglycine (DHPG)-induced epileptic hyperexcitability in Fmr1−/y mice (Chuang et al., 2005; Bianchi et al., 2009), but we used a low DHPG concentration and focused on short epileptiform bursts rather than the longer discharges produced by high concentrations (Chuang et al., 2005). We found that hippocampal slices from Fmr1−/y mice, or wild-type (WT) animals in which Homer interactions were disrupted by a peptide that binds to long Homers, are more excitable than control WT slices. The increased excitability was associated with enhanced eCBmGluR at GABAergic synapses. CB1R antagonism reversed this epileptic phenotype in Fmr1−/y and peptide-treated WT slices. The results contribute to the understanding FXS and eCB signaling and, if extended to humans, could have translational implications.
Materials and Methods
Animals.
All experimental protocols were approved by the University of Maryland, Baltimore School of Medicine Institutional Animal Care and Use Committee, and animal handling followed national and international guidelines to minimize the numbers of animals used and mitigate pain or suffering. We used tissue from 4- to 5-week-old male Fmr1−/y and age-matched WT mice on the C57BL/6J strain (The Jackson Laboratory). To test the generality of Homer modulation of eCBmGluR, in some experiments, as noted, 5- to 6-week-old male Sprague Dawley rats (Charles River) were used.
Preparation of slices.
Animals were deeply sedated with isoflurane and decapitated. Slices, 400 μm thick, were cut on a vibratome (VT1200s; Leica) in an ice-cold extracellular recording solution (ACSF) containing the following (mm): 130 NaCl, 3 KCl, 2.5 CaCl2, 2 MgSO4, 1 NaH2PO4, 25 NaHCO3, and 10 glucose, pH 7.4 (bubbled with 95% O2, 5% CO2). Slices were stored in a holding chamber on filter paper at the interface of ACSF and a moist, oxygenated atmosphere at room temperature (22°C) for >1 h before transfer to the recording chamber (RC-27L; Warner Instruments).
Electrophysiology.
Visualized whole-cell recordings were made with a Nikon E600 microscope. Voltage-clamped CA1 pyramidal cells were filled with the following (mm): 90 CsCH3SO4, 1 MgCl2, 50 CsCl, 2 MgATP, 0.2 Cs4-BAPTA, 10 HEPES, 0.3 Tris-GTP, and 5 QX314, pH 7.2 (280–290 mOsm). If the series resistances changed by >20%, the data were discarded. For evoked EPSC (eEPSC) recordings, the GABAA receptor antagonist picrotoxin (PTX; 100 μm) was present, and a cut between CA3 and CA1 prevented recurrent seizure activity. For eIPSC recordings, NBQX (10 μm) and d-AP-5 (20 μm) were present to block glutamatergic EPSCs. eCB-insensitive perisomatic inhibitory synapses were blocked by >1 h pretreatment with the P/Q-type Ca2+-channel blocker ω-agatoxin GVIA (Wilson et al., 2001; cf. Freund and Katona, 2007; Lenz et al., 1998). eIPSCs or eEPSCs were elicited by 200-μs-long extracellular stimuli delivered at 0.2 Hz with concentric bipolar stimulating electrodes in CA1 or CA3 stratum radiatum. DHPG was applied for 3–4 min when eIPSCs were tested and for 5 min when eEPSCs were tested. To measure the DHPG-induced inhibition, the peak eIPSCs or eEPSCs were averaged as baseline during the 2 min before DHPG application and then again during the last 1 min of the application to assess the magnitude of the drug effect. Field recording pipettes containing ACSF solution were placed in CA3 stratum pyramidale, and experiments were done at 32–35°C with an ACSF perfusion rate of ∼5 ml/min. Data were collected with Axopatch 200B or Axopatch 1C amplifiers (Molecular Devices), filtered at 2 kHz, and digitized at 5 kHz with Digidata 1440 or Digidata 1200 (Molecular Devices) and Clampex 9 or 10 software (Molecular Devices).
Chemicals.
The membrane-permeable Tat-fused peptides (cf. Mao et al., 2005; Ronesi et al., 2012) mGluR5CT (YGRKKRRQRRR-ALTPPSPFR) and mGluR5MU (YGRKKRRQRRR-ALTPLSPRR) were synthesized at the University of Texas Southwestern Protein Chemistry Technology Center. Peptides were dissolved in water at 5 mm, aliquoted, stored at −20°C, and used at 5 μm. Except for SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride], all drugs were made up as 1000× stocks in distilled water, aliquoted, and frozen at −20°C. SR141716A was made up in DMSO (DMSO bath concentration was 0.02%). Once thawed, aliquots were either used or discarded after 2 months. (S)-3,5-DHPG, SR141716A, MPEP, and LY367385 [(S)-(+)-α-amino-4-carboxy-2-methylbenzeneacetic acid] were obtained from Tocris Bioscience. NBQX and d-AP-5 were from Ascent Scientific. All other drugs were from Sigma-Aldrich.
Data analysis.
χ2 tests were used to compare proportions. Statistical tests among groups were done with two-way ANOVA. The significance level for all tests was *p < 0.05. Box-and-whisker plots are shown for display purposes. Cumulative distributions were compared with the Kolmogorov–Smirnov (K–S) test (http://www.physics.csbsju.edu/stats/KS-test.n.plot_form.html).
Results
mGluR activation induces synchronized burst discharges more readily in Fmr1−/y mice than in WT mice
Bath application of the group I mGluR agonist DHPG (5 μm) to a hippocampal slice from a WT mouse first induced single-unit firing in stratum pyramidale of the CA3 area. In 6 of 21 slices, short synchronized burst discharges (mean ± SEM duration, 153 ± 13 ms; n = 60 discharges from 6 slices) began after ∼10 min and then occurred regularly with interburst intervals of 2–53 s (Fig. 1A). In contrast, in 11 of 12 slices from Fmr1−/y mice, 5 μm DHPG induced burst discharges with similar durations (150 ± 11 ms) but shorter interburst intervals than in WT slices (p < 0.01, K–S test; n = 110 discharges from 11 slices; Fig. 1B, D, gray line). The difference in probability of burst firing was significant (p < 0.01, χ2 test; Fig. 1E). Fmr1−/y slices treated with 5 μm DHPG plus the mGluR antagonists LY367385 (10 μm) and MPEP (10 μm) failed to develop bursting, confirming that the bursts result from mGluR activation (n = 4). In the 13 of 15 WT slices not showing DHPG-induced bursts within 20 min, subsequent bath application of PTX (100 μm) induced burst firing within 3 min (Fig. 1A); the interburst intervals were shorter than in the DHPG-treated slices from Fmr1−/y mice (p < 0.001, K–S test; n = 130 discharges; Fig. 1D, thick dashed line). Hence, essentially all WT slices could generate synchronized bursts but were less sensitive to DHPG than Fmr1−/y slices.
A low concentration of DHPG induces epileptic burst discharges in the CA3 region of hippocampal slices from Fmr1−/y mice. A, Field recording in CA3 stratum pyramidale of a WT mouse hippocampal slice after addition of 5 μm DHPG in the perfusate. Generally, DHPG induced strong single-unit discharges, but not synchronized activity, until 100 μm PTX was added. B, In most slices from Fmr1−/y mice, 5 μm DHPG induced synchronized activity within 20 min. C, CA3 field recordings after DHPG application for 15 min in WT slices preincubated with Homer scaffold disrupting CT peptide (C1) and control MU peptide (C2). D, Interspike intervals of the synchronized discharges in slices under different conditions. E, Probability of synchronized discharge induction by DHPG under various conditions. LY, LY367385. *p < 0.05, **p < 0.01.
WT slices with disrupted Homer protein interactions have enhanced burst firing susceptibility
Homer scaffold disruption in WT slices mimics some phenotypes, such as prolonged neocortical up states, of Fmr1−/y slices (Ronesi et al., 2012). To determine whether Homer binding disruption mimicked the mGluR hyperexcitability phenotype of Fmr1−/y, we incubated WT slices with a cell-permeable, Tat-fused peptide having the PPXXF motif of the mGluR5 C-terminal tail (CT peptide) that binds the EVH1 domain of Homer (see Materials and Methods). Control slices received a Tat-fused peptide having a mutated Homer binding motif, the MU peptide, that does not interfere with Homer scaffolds. To confirm that the CT peptide reduced mGluR5–Homer coupling, we used coimmunoprecipitation of mGluR5 and Homer and found (cf. Ronesi et al., 2012) that the CT peptide reduced the coupling to 39 ± 8% of control levels (n = 3 animals; p = 0.005), whereas the MU peptide was inactive (n = 3 animals; p = 0.55; data not shown).
In MU peptide-treated slices, short bursts were elicited by DHPG in only 2 of 10 WT slices, similar to untreated WT slices (p = 0.94, χ2 test). However, after CT peptide incubation, 9 of 13 WT slices showed burst discharges (p < 0.05, χ2 test; Fig. 1C,E), a probability indistinguishable from that of Fmr1−/y slices (p = 0.37, χ2 test). In the responsive CT-treated WT slices, synchronized bursts (n = 90) had shorter interburst intervals than in the responsive MU-treated slices (n = 20; p < 0.01, K–S test; Fig. 1D, dotted line). Evidently, disruption of Homer scaffold enhances overall excitability.
Homer disruption alters eCBmGluR at hippocampal excitatory and inhibitory synapses
Fmr1−/y slices have increased eCBmGluR activity at inhibitory synapses (Zhang and Alger, 2010). The elevated sensitivity to DHPG-induced burst firing in CT-treated slices, which mimics Fmr1−/y hypersensitivity, suggests that Homer disruption might also increase eCBmGluR at inhibitory synapses.
To test this hypothesis, we measured eCBmGluR first in rat hippocampal slices (Fig. 2A). At CA1 inhibitory synapses, 2, 5, 10, and 20 μm DHPG, applied for 3–4 min, reversibly reduced eIPSCs by 13 ± 4, 22 ± 3, 47 ± 5, and 63 ± 6%, respectively (n = 5 for each concentration). CT peptide treatment significantly enhanced the DHPG effects at 2, 5, and 10 μm (Fig. 2B), with the eIPSCs being inhibited by 27 ± 3, 54 ± 4, and 65 ± 5%, respectively (n > 8; p < 0.001, two-way ANOVA). At 20 μm, DHPG reduced eIPSCs by 72 ± 6% (n = 7), similar to control, indicating a ceiling effect. Such short-term mGluR activation avoids LTD induction (cf. Heifets and Castillo, 2009). The MU peptide did not affect eCBmGluR (11 ± 3, 24 ± 4, 52 ± 4, and 59 ± 4% for 2, 5, 10, and 20 μm DHPG, respectively; n > 6; p = 0.75, two-way ANOVA). Finally, the CB1R antagonist SR141716A, at 5 μm (slices pretreated for >2 h), abolished the effects of DHPG in CT peptide-treated slices (n = 4).
CT peptide enhances DHPG-induced eCB inhibition of eIPSCs. A, Responses of eIPSCs to 5 μm DHPG (3 min application) in rat slices treated with CT (top) or MU (bottom) peptides. B, Pooled data of DHPG-induced inhibition of IPSCs. Note that the CB1R antagonist SR141716A (5 μm; SR) completely blocked the DHPG-induced inhibition (circle). C, Suppression of eIPSCs in response to 1 s depolarization of postsynaptic pyramidal neurons to 0 mV (DSI) in peptide-treated rat slices. D, Pooled DSI data in response to a range of depolarization durations. E, Responses of eEPSCs to 20 μm DHPG in rat slices. F, Pooled data of DHPG-induced inhibition of eEPSCs. Note that neither 5 μm DHPG nor the CT peptide had significant effect on eEPSCs, whereas CT treatment suppressed the eEPSC inhibition produced by higher DHPG concentrations. *p < 0.05, **p < 0.01.
We also tested the effects of Homer disruption on Ca2+-induced eCB mobilization by measuring depolarization-induced suppression of inhibition (DSI) in pyramidal neurons. Depolarization steps from −70 to 0 mV lasting 0.5, 1, or 2 s reduced eIPSC amplitudes to the same extent in rat slices treated with either CT or MU peptides (by 33 ± 4, 43 ± 5, and 55 ± 5% for CT and 31 ± 4, 43 ± 3, and 49 ± 5% for MU, respectively; n > 9 for CT and n > 7 for MU; p = 0.16). Although DSI is an eCB- and CB1R-dependent process, it is produced solely by a rise in [Ca2+]i and uses biochemical pathways distinct from those of eCBmGluR (Kano et al., 2009). The negative results on DSI demonstrate that the CT peptide does not affect CB1R function, eCB release from pyramidal cells, or the coupling between the rise in postsynaptic [Ca2+]i and eCB mobilization. Importantly, DSI is also unaffected in Fmr1−/y CA1 (Zhang and Alger, 2010).
Compared with its effects on eIPSCs, DHPG had relatively weak effects on eEPSCs, and only at doses ≥20 μm did it significantly inhibit eEPSCs, decreasing them by 23 ± 6 and 39 ± 3% at 20 and 50 μm, respectively (Figs. 2E,F). Nevertheless, in CT-treated slices, the DHPG-induced inhibition of eEPSCs was significantly reduced (to 7 ± 2 and 14 ± 4% at 20 and 50 μm, respectively; n = 4; p < 0.001, two-way ANOVA). Thus, Homer disruption has two diametrically opposed effects: it enhances eCBmGluR at inhibitory synapses but decreases eCBmGluR at excitatory synapses. Although both effects would normally shift the excitation/inhibition balance toward excitation, because 5 μm DHPG did not significantly affect the amplitudes of eEPSCs in either condition (Fig. 2F), the shift of the excitation/inhibition balance caused by the peptide at this low concentration of DHPG is attributable to its effects on inhibitory synapses.
Disruption of Homer scaffold fails to enhance eCB signal in Fmr1−/y slices
In Fmr1−/y mice, the coupling between mGluR5 and structural Homer proteins is decreased (Ronesi and Huber, 2008) and therefore the CT peptide does not increase the severity of the Homer scaffold-dependent Fmr1−/y phenotype (Ronesi et al., 2012). If there is a link between Homer proteins and Fmr1 deletion related to eCB mobilization, the effects of the CT peptide on eCBmGluR should be occluded in Fmr1−/y tissue.
To test this prediction, we first replicated the enhancing effect of the CT peptide on eCBmGluR in WT mouse slices. DHPG at 2, 5, and 10 μm reduced eIPSCs by11 ± 3, 33 ± 5, and 56 ± 5%, respectively (n > 7; Fig. 3A) in the control slices. In contrast, in the presence of the CT peptide, DHPG reduced the eIPSCs by 30 ± 3, 52 ± 3, and 70 ± 5%, respectively, i.e., a highly significant enhancement of inhibition (n > 8; p < 0.001, two-way ANOVA), whereas the MU peptide had no effect on DHPG-induced inhibition (12 ± 3, 35 ± 6, and 53 ± 2%, respectively; n > 6; p = 0.57, two-way ANOVA). In slices from Fmr1−/y mice, DHPG at 2, 5, and 10 μm reduced eIPSCs by 23 ± 3, 50 ± 4, and 63 ± 3%, respectively, which was significantly more than in WT slices (n > 9; p < 0.001, two-way ANOVA) but not different from the inhibition in CT peptide-treated WT slices (p = 0.42, two-way ANOVA; Fig. 3A).
CT peptide enhances DHPG-induced eCB inhibition of eIPSCs in slices from WT mice (A) but not Fmr1−/y mice (B). Note that 5 μm DHPG-induced inhibition of IPSCs was fully blocked by the CB1R antagonist SR141716A (5 μm; circle) or the group I mGluR antagonists MPEP (10 μm) and LY367385 (10 μm; triangle). *p < 0.05, **p < 0.01.
Most importantly, incubation of Fmr1−/y slices with either the CT or MU peptides did not change the DHPG-induced reduction of eIPSCs (22 ± 3, 53 ± 8, and 62 ± 4% for CT and 29 ± 3, 49 ± 5, and 65 ± 7% for MU, respectively; n > 7; p > 0.05, two-way ANOVA). Finally, either 5 μm SR141716A or a combination of 10 μm MPEP and 10 μm LY367385 abolished the effects of 10 μm DHPG in CT peptide-treated Fmr1−/y slices (n = 3), confirming that DHPG reduced the eIPSCs via eCBmGluR.
CB1R antagonism suppresses DHPG-induced burst firing
We hypothesized that the heightened epileptiform burst susceptibility of Fmr1−/y slices is attributable to eCBmGluR-induced excitatory/inhibitory imbalance, which predicts that CB1R blockade would reverse the imbalance and prevent burst firing. To test this prediction, we incubated Fmr1−/y slices with 5 μm SR141716A to block CB1Rs before applying 5 μm DHPG. No field potential bursts were observed in 12 of 13 SR141716A-treated slices within 20 min after DHPG application, although asynchronous single-unit spike firing was greatly enhanced (Fig. 4B). In the slice in which bursting occurred, the interburst intervals were much longer than normal (n = 20 discharges; p < 0.01, K–S test; Fig. 4C). Restoring the excitatory/inhibitory imbalance by blocking all inhibitory synaptic transmission with 100 μm PTX reinstated the epileptic activity in all six of the nonresponsive slices tested (p < 0.001, χ2 test; Figs. 4B,D). In CT-treated WT slices, SR141716A incubation also greatly suppressed the epileptogenesis (p < 0.001, χ2 test; Fig. 4D): DHPG-induced synchronized bursts in only 1 of 10 slices, and the interburst intervals were longer than normal (n = 20 discharges; p < 0.01, K–S test).
Low concentration of DHPG induces population burst firing in Fmr1−/y slices that depends on eCBs. A, Field recording of activity induced by 5 μm DHPG in CA3 stratum pyramidale of an Fmr1−/y mouse hippocampal slice. B, Responses of an Fmr1−/y slice preincubated with the CB1R antagonist SR141716A to DHPG and PTX. Note the DHPG-induced strong single-unit discharges, but absence of burst firing, before PTX application. C, Interspike intervals of the burst discharges in slices. D, Probability of DHPG-induced burst discharges in slices under different conditions. Blockade of CB1Rs greatly suppressed the epileptic activity in both Fmr1−/y and CT-treated WT slices. SR, SR141716A. *p < 0.05, **p < 0.01.
Discussion
We report novel findings on excitability control in the FXS mouse model. (1) Disruption of Homer scaffolds increased group I mGluR-stimulated epileptiform discharges (Chuang et al., 2005) whether the disruption was caused by the deletion of Fmr1 or a membrane-permeable CT peptide. (2) Antagonism of CB1R activity prevented development of hyperexcitability in both models, implying that the eCB system was affected by disruption of mGluR–Homer interactions. (3) The CT peptide enhanced eCBmGluR at inhibitory synapses but decreased it at excitatory synapses, exactly replicating observations in the Fmr1−/y mouse, in which eCBmGluR is increased at inhibitory (Maccarrone et al., 2010; Zhang and Alger, 2010) and decreased at excitatory (Jung et al., 2012) synapses.
The alterations of eCBmGluR in Fmr1−/y are probably related to changes in Homer binding, because Homer 1a overexpression also decreases eCBmGluR at excitatory synapses in cell cultures (Roloff et al., 2010). The molecular organization of the eCBmGluR system is well understood at excitatory synapses (Lafourcade et al., 2007; Katona and Freund, 2008). There, the decrease in eCBmGluR in Fmr1−/y is attributed to translocation of Diacylglycerol lipase-alpha (DGLα) to spine necks from its usual position near perisynaptic mGluRs in the spine head (Jung et al., 2012). Homers are required to localize DGLα near the plasma membrane (Jung et al., 2007) and facilitate detection of eCBmGluR signaling in expression systems (Won et al., 2009). It is likely that disrupted Homer binding accounts for the abnormal positioning of DGLα in Fmr1−/y (Jung et al., 2012), although this has not been tested. Importantly, no alteration in DGLα localization was observed at inhibitory synapses (Jung et al., 2012). Indeed, the molecular complex that generates eCBs at perisomatic inhibitory synapses is not known. Finding that eCBmGluR is increased at perisomatic inhibitory synapses by the CT peptide and in Fmr1−/y tissue (Maccarrone et al., 2010; Zhang and Alger, 2010) suggests that the intact Homer scaffold ordinarily opposes full eCBmGluR expression at these synapses (Fig. 2B).
The densities of both mGluR5 and DGLα are much lower in pyramidal cell somata than dendrites (Katona et al., 2006; Yoshida et al., 2006; Kano et al., 2009). These observations, together with the absence of somatic glutamatergic terminals, suggest that 2-arachidonoylglycerol (2-AG) from dendritic regions could diffuse back and affect perisomatic inhibitory terminals. In this case, disruption of Homer scaffolds would change the localization of mGluR5 and/or DGLα in spines or dendrites to favor 2-AG diffusion toward somata. However, the presence of active uptake and degradation systems (Kano et al., 2009), together with evidence that dendritically produced 2-AG cannot diffuse more than ∼10 μm (Chevaleyre and Castillo, 2004), argues that dendritic 2-AG spillover cannot reach perisomatic synapses. Alternatively, despite their low densities, mGluR5 and DGLα in somata may mobilize sufficient 2-AG locally via glutamate spillover from dendrites or astrocytes in stratum pyramidale. The higher concentrations of CB1Rs on somatic terminals makes them much more sensitive to eCBs than dendritic terminals (Kano et al., 2009). Bath application of group I mGluR agonists or inhibition of glutamate uptake enhances DSI (Morishita and Alger, 1999), mediated by the somatic eCBmGluR system.
The enhancing effect of Homer disruption at inhibitory synapses could reflect a different basal arrangement of Homer–mGluR5 coupling on somata. For example, Homer disruption could release mGluR5 from binding to other proteins, increasing its availability to stimulate 2-AG synthesis. Interestingly, activation of DGLα is independent of Homer binding; DGLα generates 2-AG equally well when Homer binding is prevented (Jung et al., 2007). Fully understanding the Homer modulation of eCBmGluR at perisomatic inhibitory synapses will require elucidating the molecular organization of the eCBmGluR system.
Other Homer binding partners, including DGLα, have the same proline-rich binding motif (PPXXF) found in mGluR5 (Jung et al., 2007). The CT peptide could disrupt coupling of Homer to these partners as well. Homer proteins act collectively as a molecular switch that reprioritizes mGluR signaling, with some mGluR-mediated processes being inhibited and some facilitated by Homers (Kammermeier, 2008; Won et al., 2009). The CT peptide does not reduce Homer or mGluR levels, membrane localization, activation of phospholipase C, elevation of intracellular Ca2+ (Mao et al., 2005), or basal synaptic transmission (Ronesi and Huber, 2008; Ronesi et al., 2012), and we show that the CT peptide also does not affect DSI, i.e., that it has no effect on GABAA receptors, Ca2+ influx, eCB release, or binding to CB1Rs. CT peptide-mediated Homer scaffold disruption mimics some phenotypical features of Fmr1−/y in WT neocortical slices (Ronesi et al., 2012), and CT has little effect in Fmr1−/y neocortex, as expected if Homer-dependent interactions are already compromised. Thus, it is reasonable to attribute CT peptide effects to disruption of Homer scaffolds. In the hippocampus, depolarization-induced suppression of excitation (DSE) is markedly weaker than DSI and difficult to measure (Wagner and Alger, 1996; Ohno-Shosaku et al., 2002). The biochemical mechanisms of DSE and DSI appear to be identical (Hashimotodani et al., 2005; Tanimura et al., 2010); hence, it is likely that DSE is unchanged by Homer modulation, although this should be tested in tissue with robust DSE (e.g., cerebellum; Kreitzer and Regehr, 2001).
The ability of DHPG to induce eCB LTD is very sensitive to experimental details, especially concentration and duration of DHPG application. Generally, high concentrations and long durations are needed for eCB LTD at CA1 excitatory synapses (Xu et al., 2010; Péterfi et al., 2012). However, others (Rouach and Nicoll, 2003; Nosyreva and Huber, 2005) failed to observe an eCBmGluR-dependent component of LTD under conditions like ours, suggesting that technical details may account for variability in observing eCB LTD. At CA1 perisomatic inhibitory synapses, we showed (Zhang and Alger, 2010) that normally 5 μm DHPG produces reversible IPSC suppression, whereas 50 μm is required for eCB LTD, but that in the Fmr1−/y mouse, 5 μm DHPG does induce LTD. Here, we applied DHPG for only 3–4 min to eIPSCs and 5 min to eEPSCs to avoid inducing LTD so that we could efficiently assess the inhibition caused by different concentrations of DHPG. eCB LTD remains to be studied.
Seizure susceptibility is increased in Fmr1−/y mice and FXS patients (Musumeci et al., 1999). We investigated the brief epileptiform burst potentials elicited with low DHPG concentrations. These brief bursts resemble the short bursts emerging immediately after mGluR activation by high concentrations of DHPG or GABAA receptor blockade (Chuang et al., 2005). We did not observe the prolonged epileptiform bursts, even 1 h after DHPG application, probably because we used low DHPG concentrations, a lower experimental temperature, and a submersion-type chamber (rather than an interface-type chamber; cf. Chuang et al., 2005). It will be important to examine CB1R sensitivity of the prolonged mGluR-induced discharges produced by high DHPG concentrations in Fmr1−/y (Chuang et al., 2005).
Broadly speaking, seizures arise from an imbalance of excitation and inhibition toward excitation, and the underlying mechanisms may include alterations in the strength of excitatory and/or inhibitory synapses, neuronal network oscillations, and rewiring of neuronal circuits. Although CB1Rs exist on both excitatory and inhibitory synaptic terminals, their density in the hippocampus is much higher at inhibitory terminals (Katona and Freund, 2008; Kano et al., 2009). Hence, widespread action of eCBs may suppress inhibition more than excitation and thereby promote hyperexcitability. This may be particularly important when eCB mobilization occurs, such as with group I mGluR activation. Hippocampal pyramidal cells densely express group I mGluRs, and, in response to DHPG application, these neurons fire action potentials (Fig. 1A). Meanwhile, as we have shown, DHPG at a low concentration suppresses perisomatic inhibitory transmission but has no effect on excitatory synapses (Fig. 2). This will push the neuronal circuit toward its limit in maintaining normal excitability. Any additional shift toward excitation, such as additional eCB mobilization by higher DHPG, Homer disruption (Fig. 1), or Fmr1 malfunction (Fig. 1; Ronesi et al., 2012), will greatly increase the chance of epileptogenesis. Importantly, a similar increase in eCB signaling at GABAergic synapses has been reported in a febrile seizure model (Chen et al., 2007), and blockade of CB1Rs reduced epileptiform activity there. However, these results differ from those obtained with the kainic acid model in which eCB actions on hippocampal glutamatergic nerve terminals are the most important for neuroprotection (Monory et al, 2006). The difference may be explained by the fact that kainic acid inhibits GABA release (Fisher and Alger, 1984; Carta et al. 2014) including GABA release from CB1R+ interneurons (Lourenco et al., 2010). Kainic acid suppression of this inhibition will contribute to epileptogenic activity, and by depressing release from CB1R+ interneurons, also occlude the influence of eCBs on inhibition in this seizure model.
Our results suggest that at least the early stages of hyperexcitability associated with excessive eCB actions in FXS could be reversed by CB1R antagonism rather than by their activation. Indeed, numerous phenotypic features of Fmr1−/y mice, including their elevated audiogenic seizure susceptibility, can be reversed by genetic elimination or pharmacological blockade of CB1Rs (Busquets-Garcia et al., 2013). We suggest that related therapeutic opportunities in FXS may be associated with the Homer scaffold system.
Footnotes
This work was supported by National Institutes of Health Grant RO1 MH077277 and a program grant from the FRAXA Research Foundation (B.E.A.).
The authors declare no competing financial interests.
- Correspondence should be addressed to Dr. Ai-Hui Tang, Department of Physiology, University of Maryland, 655 West Baltimore Street, Baltimore, MD 21201. tangaihui{at}gmail.com
References
In this issue
